Table 1.

Clinical information for each patient from whom primary fibroblasts or organoids were derived and references to associated cell culture and genomic information

Patient	Organoid	Sanger Cell Model Passports ID	CAF	Age	Sex	Histology	Clinical stage	Pathological stage	Neoadjuvant treatment	Tumor regression grade
005	OESO-005	HCM-SANG-0290-C15	N/A	68	M	adenocarcinoma	cT3N2M0	ypT3N2M0	ECX	4
191	OESO-191	HCM-SANG-0543-C15	N/A	60	M	adenocarcinoma	cT3N0M0	ypT3N0M0	CAPOX	4
195	OESO-195	HCM-SANG-0546-C15	N/A	72	M	adenocarcinoma	cT2N1M0	ypT2N1M0	FLOT	3
669	N/A	N/A	CAF669	71	F	adenocarcinoma	cT2N0M0	pT2N0M0	none	N/A
1412	N/A	N/A	CAF1412	81	M	adenocarcinoma	cT3N1M0	pT3N3M0	none	N/A

M, male; F, female; ECX, epirubicin, cisplatin, and capecitabine; CAPOX, capecitabine and oxaliplatin; FLOT, 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel.